PARP1 rs1136410 Val762Ala contributes to an increased risk of overall cancer in the East Asian population: a meta-analysis

Yijuan Xin, Liu Yang, Mingquan Su, Xiaoli Cheng, Lin Zhu and Jiayun Liu

Abstract

Objectives: To investigate the association between poly(ADP-ribose) polymerase 1 (PARP1) rs1136410 Val762Ala and cancer risk in Asian populations, as published findings remain controversial.

Methods: The PubMed and EMBASE databases were searched, and references of identified studies and reviews were screened, to find relevant studies. Meta-analyses were performed to evaluate the association between PARP1 rs1136410 Val762Ala and cancer risk, reported as odds ratio (OR) and 95% confidence interval (CI).

Results: A total of 24 studies with 8,926 cases and 15,295 controls were included. Overall, a significant association was found between PARP1 rs1136410 Val762Ala and cancer risk in East Asians (homozygous: OR 1.19, 95% CI 1.06, 1.35; heterozygous: OR 1.10, 95% CI 1.04, 1.17; recessive: OR 1.13, 95% CI 1.02, 1.25; dominant: OR 1.13, 95% CI 1.06, 1.19; and allele comparison: OR 1.09, 95% CI 1.03, 1.15). Stratification analyses by race and cancer type revealed similar results for gastric cancer among the Chinese population.

Conclusion: The findings suggest that PARP1 rs1136410 Val762Ala may be significantly associated with an increased cancer risk in Asians, particularly the Chinese population.

Keywords

PARP1, Val762Ala, cancer, risk, meta-analysis

Date received: 28 October 2020; accepted: 18 January 2021

Corresponding author:
Jiayun Liu, Department of Clinical Laboratory, Xijing Hospital, Fourth Military Medical University 15 Changle West Road, Xian 710032, Shaanxi, China.
Email: jiayun@fmmu.edu.cn
## Introduction

Cancer is a major public health problem worldwide and is recognized to rank as the leading cause of death in the 21st century. Incidence and mortality rates of various cancers continue to increase rapidly worldwide, with approximately 18.1 million new cases and 9.6 million cancer-related deaths in 2018.\(^1\) However, about 48% of new cases and 57% of cancer deaths occurred in Asia.\(^1\) Both genetic and environmental factors contribute to carcinogenesis.\(^2\) Environmental agents, including ultraviolet light, inhaled cigarette smoke and incompletely defined diet, can often cause DNA damage that may lead to carcinogenesis. Several pathways exist to monitor and correct such damage, including the base excision repair (BER) system, which plays an important role in excising and replacing the damage mainly arising from endogenous oxidative and hydrolytic decay.\(^3,4\)

Poly(ADP-ribose) polymerase-1 (PARP1), also named adenosine diphosphate ribosyl transferase (ADPRT), is a key component of the BER system.\(^5\) In the presence of DNA breaks, the catalytic activity of PARP1 has been shown to be stimulated more than 500-fold and PARP1 is assumed to play multifunctional roles in various biological functions, including cell survival, cell death programmes, transcriptional regulation, telomere cohesion and mitotic spindle formation.\(^5\) PARP1 deficiency in female mice has been reported to cause mammary carcinogenesis, suggesting PARP1 may be a possible risk factor for breast cancer in humans.\(^6\) Accumulating evidence implicates PARP1 deficiency as a contributing factor to carcinogenesis. The human \(PARP1\) gene lies in chromosome 1q41-42, spanning 47.3 kb in length and containing 23 exons. To date, more than 1000 single nucleotide polymorphisms (SNPs) have been identified for \(PARP1\). Among them, the Val762Ala (rs1136410 A \(\rightarrow\) G) polymorphism is the most investigated.\(^7-10\) Ala762 has been found to display almost half the activity of Val762, influencing the ability to repair and, thus, possible carcinogenesis.\(^11\)

A number of previous studies have investigated the association between \(PARP1\) rs1136410 Val762Ala and cancer risk. However, the findings remain controversial and inconclusive. The latest meta-analyses were conducted in 2013 to study the association between this polymorphism and overall cancer risk in all ethnicities.\(^7,8\) No previously published meta-analysis has focused only on Asian populations. Therefore, the aim of the present study was to perform a meta-analysis investigating the association between \(PARP1\) rs1136410 Val762Ala and cancer risk primarily in an Asian population, and particularly in the Chinese population.

## Materials and methods

### Search strategy

To retrieve all relevant studies, the PubMed and EMBASE electronic databases were searched for articles published in Chinese or English, up to June 2020, using the following terms: ‘PARP1 or PARP-1 or poly (ADP-ribose) polymerase 1 or ADPRT’ or ‘polymorphism or variant or variation’ or ‘cancer or carcinoma or tumor’. In addition, references in review articles and the identified studies were manually screened to identify additional relevant studies. Only the largest or the latest study was included in the meta-analysis. Two independent researchers (YX ad JL) screened titles and abstracts of articles retrieved in the search, followed by full-text evaluation for articles that met the inclusion criteria.

### Inclusion and exclusion criteria

For inclusion into the present meta-analysis, studies must have satisfied the following criteria: (1) investigating the
association between the *PARP1* rs1136410 Val762Ala polymorphism and cancer risk in an Asian study population; (2) cohort or case-control design; and (3) enough information for estimation of odds ratios (ORs) and their 95% confidence intervals (CIs). Studies were excluded if the following criteria were met: (1) case only studies; (2) reviews, meta-analyses and comments; or (3) insufficient information for calculation. Studies with genotype frequencies in the controls that departed from Hardy–Weinberg equilibrium (HWE) were also excluded, unless further evidence indicated that other polymorphisms were in HWE.

**Data extraction and quality score**

Two investigators (YX and JL) independently extracted the following information from each eligible publication: author surname, year of publication, country of origin, cancer type, source of control, and distribution of alleles and genotypes. In case of any disagreement, the issue was resolved by discussion with a third investigator (YL). The quality of each study was evaluated using previously published quality assessment criteria. The quality score ranged from 0–15, with scores of 0–9 considered to be low quality, and scores of 10–15 considered to be high quality.

This work was performed under PRISMA guidelines for conducting systematic reviews and meta-analyses. All analyses were based on previously published studies; therefore, no ethics approval or patient consent were required.

**Statistical analyses**

Goodness-of-fit χ²-test was applied to estimate HWE, and a *P* value < 0.05 was considered significant and indicated that the study departed from HWE. The strength of association between the *PARP1* rs1136410 Val762Ala polymorphism and cancer risk in Asians was evaluated by crude ORs and their corresponding 95% CIs under the five genetic models: homozygous model (Ala/Ala versus Val/Val), heterozygous model (Val/Ala versus Val/Val), recessive model (Ala/Ala versus Val/Ala + Val/Val), dominant model (Val/Ala + Ala/Ala versus Val/Val) and allele comparison model (Ala versus Val). Q-test was performed to assess heterogeneity among the studies. A *P* value > 0.10 indicated no significant heterogeneity, in which case the fixed-effects model (Mantel–Haenszel method) was used. Otherwise, the random-effects model (DerSimonian and Laird method) was applied. Stratification analyses were also performed to test the association regarding race, cancer type and source of control. Moreover, Begg’s funnel plot and Egger’s linear regression test was adopted to assess the potential publication bias. All statistical analyses were conducted using STATA software, version 11.0 (Stata Corporation, College Station, TX, USA). A *P* value less than 0.05 was considered statistically significant.

**Trial sequential analysis**

Trial sequential analysis (TSA) was used to evaluate whether the quantitative results were reliable. TSA was performed by anticipating a 20% relative risk reduction, a 5% type I error, and a statistical test power of 80%. If the cumulative Z-curve crossed the TSA monitoring boundary, or exceeded the required information size, firm evidence had been reached. Otherwise, more studies were needed.

**Genotype-based mRNA expression analysis**

Expression quantitative trait loci (eQTL) analysis in the genotype-tissue expression (GTEx) portal (https://www.gtexportal.org/home/)
was used to evaluate correlations between the PARP1 rs1136410 Val762Ala polymorphism and levels of mRNA expression.

**Results**

**Characteristics of eligible studies**

As shown in Figure 1, a total of 519 articles were identified from PubMed, EMBASE, and from manually screening reviews and references. After title and abstract screening, 38 articles satisfied the inclusion criteria and underwent further full text evaluation. Among them, 10 were excluded for no Asian population, two for insufficient information and two deviated from HWE. In order to enlarge the sample size, six articles were included in the final analysis due to other polymorphisms that were in HWE. Finally, 24 studies comprising 8,926 cases and 15,295 controls were subjected to the final meta-analysis.

![Flow diagram showing selection of studies included in the current meta-analysis.](image)

The characteristics of all the identified studies are listed in Table 1. There were five studies focused on gastric cancer, four on lung cancer, two each on breast and colorectal cancer, and other cancers represented by only one study. In terms of race, 19 studies were conducted in the Chinese population, three in Japanese participants and two in the Korean population. Thus, all studies involved participants from East Asia. Out of the selected studies, 20 were hospital-based (HB) and four were population-based (PB). A total of 16 studies were considered to be of high quality and eight were of low quality.

**Meta-analysis results**

Main findings regarding the association between the PARP1 rs1136410 Val762Ala polymorphism and cancer risk in the East Asian population are shown in Table 2. A significant association was found between
| Author and reference No. | Publication Year | Country | Race | Cancer type | Control source | Sample size Cases | Case genotypes | Control genotypes | MAF | HWE | Score |
|-------------------------|-----------------|---------|------|-------------|----------------|--------------------|----------------|-------------------|-----|-----|-------|
| Hao et al.23            | 2004 China      | Chinese | Esophageal | Esophageal | HB             | 414 479 125 212 77 168 230 81 | 0.41 0.880 | 13 |
| Zhang et al.24          | 2005 China      | Chinese | Lung | Lung | HB             | 1000 1000 307 509 184 359 504 137 | 0.39 0.057 | 12 |
| Miao et al.17           | 2006 China      | Chinese | Gastric | Gastric | HB             | 500 1000 150 257 93 396 492 112 | 0.36 0.026 | 11 |
| Zhai et al.25           | 2006 China      | Chinese | Breast | Breast | HB             | 302 639 100 153 49 197 331 111 | 0.43 0.164 | 10 |
| Zhang et al.22          | 2006 China      | Chinese | Gastric | Gastric | HB             | 236 708 76 109 51 258 367 83 | 0.38 0.006 | 8 |
| Stern et al.26          | 2007 Singapore  | Chinese | Colorectal | Colorectal | PB             | 307 1173 93 150 64 381 564 228 | 0.43 0.457 | 13 |
| Chiang et al.27         | 2008 China      | Chinese | Thyroid | Thyroid | HB             | 283 469 86 139 58 168 221 80 | 0.41 0.616 | 11 |
| Jin et al.28            | 2010 Korea      | Korean  | NHL | NHL | PB             | 573 721 189 279 105 221 354 146 | 0.45 0.845 | 12 |
| Wang et al.29           | 2010 China      | Chinese | Bladder | Bladder | HB             | 234 253 68 120 46 78 127 48 | 0.44 0.771 | 10 |
| Kim et al.30            | 2011 Korea      | Korean  | Gastric | Gastric | HB             | 151 320 42 70 39 102 161 57 | 0.43 0.635 | 7 |
| Nakao et al.18          | 2012 Japan      | Japanese | Pancreatic | Pancreatic | HB             | 185 1465 61 90 34 550 657 258 | 0.40 0.012 | 11 |
| Pan et al.19            | 2012 China      | Chinese | Gastric | Gastric | PB             | 176 308 60 79 37 105 132 71 | 0.44 0.020 | 9 |
| Wen et al.20            | 2012 China      | Chinese | Gastric | Gastric | HB             | 307 307 96 154 57 105 132 70 | 0.44 0.024 | 9 |
| Yuan et al.31           | 2012 China      | Chinese | Head and neck | Head and neck | HB             | 395 883 138 193 64 300 431 152 | 0.42 0.895 | 10 |
| Zhang et al.32          | 2012 China      | Chinese | Cervical | Cervical | HB             | 80 176 25 39 16 54 83 39 | 0.46 0.508 | 8 |
| Hosono et al.33         | 2013 Japan      | Japanese | Endometriat | Endometriat | HB             | 91 261 29 47 15 100 121 40 | 0.39 0.734 | 8 |
| Li et al.34             | 2013 China      | Chinese | Colorectal | Colorectal | HB             | 451 626 134 228 89 222 319 85 | 0.39 0.078 | 9 |
| Tang et al.35           | 2013 China      | Chinese | Breast | Breast | HB             | 793 845 250 405 138 275 419 151 | 0.43 0.694 | 11 |
| Xue et al.36            | 2013 China      | Chinese | Lung | Lung | HB             | 410 410 129 202 79 138 205 67 | 0.41 0.531 | 10 |
| Zeng et al.21           | 2013 Japan      | Japanese | Cholangiocarcinoma | Cholangiocarcinoma | HB             | 94 94 40 11 43 35 11 48 | 0.57 < 0.001 | 6 |
| Wang et al.37           | 2015 China      | Chinese | Lung | Lung | HB             | 500 500 151 252 97 140 251 109 | 0.47 0.860 | 10 |
| Yu et al.38             | 2015 China      | Chinese | Lung | Lung | HB             | 373 360 163 164 46 162 164 34 | 0.32 0.415 | 10 |
| Cheng et al.39          | 2019 China      | Chinese | Neuroblastoma | Neuroblastoma | PB             | 469 998 136 244 89 330 482 186 | 0.43 0.669 | 13 |
| Deng et al.40           | 2019 China      | Chinese | Glioma   | Glioma   | HB             | 602 1300 185 303 114 432 564 227 | 0.42 0.684 | 13 |

HB, hospital based; PB, population based; NHL, non-Hodgkin lymphoma; MAF, minor allele frequency; HWE, Hardy–Weinberg equilibrium.
Table 2. Meta-analysis of the association between the poly(ADP-ribose) polymerase 1 (PARP1) rs1136410 Val762Ala and cancer risk in East Asians.

| Variable                | Homozygous | Heterozygous | Recessive | Dominant | Allele comparison |
|-------------------------|------------|--------------|-----------|----------|------------------|
|                         | Ala/Ala versus Val/Val | Val/Ala versus Val/Val | Ala/Ala versus (Val/Ala + Val/Val) | (Val/Ala + Ala/Ala) versus Val/Val | Ala versus Val |
|                         | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| East Asians             | 1.19 (1.06, 1.35) | 1.10 (1.04, 1.17) | 1.13 (1.02, 1.25) | 1.13 (1.06, 1.19) | 1.09 (1.03, 1.15) |
| Race                    | 1.22 (1.07, 1.39) | 1.11 (1.04, 1.19) | 1.15 (1.02, 1.29) | 1.14 (1.07, 1.21) | 1.10 (1.04, 1.17) |
| Chinese                 | 1.14 (0.59, 2.21) | 0.95 (0.76, 1.18) | 1.16 (0.65, 2.07) | 0.97 (0.79, 1.19) | 1.06 (0.77, 1.46) |
| Korean                  | 1.08 (0.78, 1.49) | 1.23 (0.93, 1.62) | 0.99 (0.74, 1.33) | 1.16 (0.90, 1.48) | 1.06 (0.88, 1.28) |
| Japanese                | 1.22 (0.90, 1.66) | 1.07 (0.94, 1.22) | 1.19 (0.93, 1.52) | 1.11 (0.99, 1.26) | 1.09 (0.95, 1.25) |
| Lung                    | 1.46 (0.98, 2.18) | 1.20 (1.03, 1.39) | 1.34 (0.91, 1.98) | 1.28 (1.11, 1.47) | 1.19 (1.01, 1.41) |
| Gastric                 | 0.96 (0.76, 1.21) | 0.87 (0.84, 1.21) | 0.95 (0.77, 1.18) | 1.00 (0.84, 1.18) | 0.98 (0.88, 1.10) |
| Breast                  | 1.41 (0.94, 2.11) | 1.14 (0.93, 1.39) | 1.30 (0.92, 1.85) | 1.20 (0.99, 1.45) | 1.17 (0.99, 1.39) |
| Colorectal              | 1.08 (0.96, 1.22) | 1.11 (1.01, 1.22) | 1.02 (0.92, 1.14) | 1.10 (1.00, 1.21) | 1.05 (0.99, 1.12) |
| Others                  | 1.24 (1.08, 1.42) | 1.11 (1.04, 1.19) | 1.17 (1.03, 1.32) | 1.15 (1.08, 1.22) | 1.11 (1.04, 1.18) |
| Control source          | 1.02 (0.85, 1.21) | 1.07 (0.93, 1.23) | 0.98 (0.84, 1.14) | 1.05 (0.92, 1.20) | 1.01 (0.93, 1.11) |

OR, odds ratio; CI, confidence interval; HB, hospital-based; PB, population-based.
the PARP1 rs1136410 Val762Ala polymorphism and cancer risk in the East Asian population (homozygous model: OR 1.19, 95% CI 1.06, 1.35, \( P = 0.004 \); heterozygous model: OR 1.10, 95% CI 1.04, 1.17, \( P = 0.001 \); recessive model: OR 1.13, 95% CI 1.02, 1.25, \( P = 0.024 \); dominant model: OR 1.13, 95% CI 1.06, 1.19, \( P < 0.001 \); and allele comparison model: OR 1.09, 95% CI 1.03, 1.15, \( P = 0.002 \)).

In the analyses of data stratified by race, a total of 19 studies with 7832 cases and 12,434 controls focused on the Chinese population. PARP1 rs1136410 Val762Ala was found to be significantly associated with an increased risk of cancer in the Chinese population under all five genetic modes (homozygous model: OR 1.22, 95% CI 1.07, 1.39, \( P = 0.004 \); heterozygous model: OR 1.11, 95% CI 1.04, 1.19, \( P = 0.001 \); recessive model: OR 1.15, 95% CI 1.02, 1.29, \( P = 0.023 \); dominant model: OR 1.14, 95% CI 1.07, 1.21, \( P < 0.001 \); and allele comparison model: OR 1.09, 95% CI 1.03, 1.15, \( P = 0.002 \); Figure 2 and Table 2). These associations were not observed in the Korean and Japanese populations (Figure 2).

In the analysis of data stratified by cancer type, PARP1 rs1136410 Val762Ala was found to be significantly associated with an increased risk of gastric cancer (heterozygous model: OR 1.20, 95% CI 1.03, 1.39, \( P = 0.018 \); dominant model: OR 1.28, 95% CI 1.11, 1.47, \( P = 0.001 \); and allele comparison model: OR 1.19, 95% CI 1.01, 1.41, \( P = 0.039 \)) and other cancers (oesophageal, thyroid, non-Hodgkin lymphoma, bladder, pancreatic, head and neck, cervical,

\[\text{Figure 2. Stratification analysis by race showing odds ratios (ORs) and 95% confidence intervals (CIs) of the association between the poly(ADP-ribose) polymerase I (PARP1) rs1136410 Val762Ala polymorphism and cancer risk in the allele comparison model.}\]
endometrial, cholangiocarcinoma, neuroblastoma, and glioma combined), but not lung, breast and colorectal cancer (Table 2).

In stratification analyses by control source, hospital-based studies were revealed to show a significant association between PARP1 rs1136410 Val762Ala and increased cancer risk (homozygous model: OR 1.24, 95% CI 1.08, 1.42, \( P = 0.001 \); heterozygous model: OR 1.11, 95% CI 1.04, 1.19, \( P = 0.002 \); recessive model: OR 1.17, 95% CI 1.03, 1.32, \( P = 0.013 \); dominant model: OR 1.15, 95% CI 1.08, 1.22, \( P < 0.001 \); and allele comparison model: OR 1.11, 95% CI 1.04, 1.18, \( P = 0.001 \); Table 2).

**Heterogeneity and sensitivity analyses**

Substantial heterogeneities were observed among all studies investigating the association between the PARP1 rs1136410 Val762Ala polymorphism and cancer risk in East Asians, under the homozygous model, \( P = 0.001 \); the recessive model, \( P = 0.002 \); and the allele comparison model, \( P = 0.006 \). The heterogeneities were not observed with the heterozygous model, \( P = 0.920 \) and the dominant model, \( P = 0.371 \). Therefore, the random-effects model was applied to evaluate the pooled ORs and their 95% CIs.

**Publication bias**

A funnel plot and the findings from Egger’s linear regression analysis suggested that no evidence of publication bias was observed (homozygous model, \( P = 0.644 \); heterozygous model, \( P = 0.615 \); recessive model, \( P = 0.755 \); dominant model, \( P = 0.429 \); and allele comparison model, \( P = 0.430 \)).

**Trial sequential analysis results**

As shown in Figure 3, TSA showed that the cumulative z-curve crossed the trial sequential monitoring boundary before reaching the required information size, suggesting that the cumulative evidence was sufficient and no further evidence was needed to verify the conclusions.

**Effect of PARP1 rs1136410 Val762Ala polymorphism on expression of PARP1**

A further assessment of the effect of PARP1 rs1136410 Val762Ala polymorphism on

![Figure 3. Trial sequential analysis (TSA) of the poly(ADP-ribose) polymerase 1 (PARP1) rs1136410 Val762Ala polymorphism under the dominant model.](image)
PARP1 mRNA expression, using the GTEx web tool, showed that the 762Val allele was significantly associated with higher levels of *PARP1* expression in whole blood (Figure 4).

**Discussion**

DNA repair pathways play a key role in maintaining genome integrity and then protecting against carcinogenesis.\(^4\) PARP1 is a molecular sensor of DNA strand breaks and its activation has an important role in the regulation of their repair.\(^5\) In response to DNA damage, PARP1 is capable of using NAD\(^{+}\) to synthesize long and branched polymers of ADP-ribose on several acceptor proteins.\(^5\) There are three functional domains within PARP1 polymerase, two zinc-finger motifs that are important for binding to DNA-strand breaks and a third one for coupling damage-induced changes to alterations in its catalytic activity.\(^4\) In addition, there is growing evidence to show that deficiency of PARP1 leads to DNA repair defects and chromatin structure instability, thereby contributing to carcinogenesis.\(^3\)

The human *PARP1* gene is located on chromosome 1q41-42. To date, more than 1000 SNPs have been identified in the *PARP1* gene. Among them, the most investigated is the Val762Ala polymorphism, an A to G nucleotide transition at codon 762 in exon 17 that results in Val762Ala substitution in the catalytic domain of PARP1.\(^4\)

A body of evidence suggests that this polymorphism is associated with altered PARP1

---

**Figure 4.** Effect of poly(ADP-ribose) polymerase 1 (*PARP1*) rs1136410 Val762Ala polymorphism on the expression of *PARP1* extracted from the genotype-tissue expression (GTEx) database. The 762Val allele was significantly associated with higher levels of *PARP1* expression in whole blood (*P* = 1.4 × 10\(^{-5}\)).
activity. For example, Wang et al.\textsuperscript{11} found that Ala762 displays almost half of the activity of Val762, and thereby may contribute to carcinogenesis.

A total of 24 studies comprising 8,926 cases and 15,295 controls were subjected to meta-analysis in the current study. The results indicated that the PARP1 rs1136410 Val762Ala polymorphism was significantly associated with an increased cancer risk in the East Asian population. In the analysis of data stratified by race, Ala762 allele was also found to be associated with an increased risk of cancer among the Chinese population, but not in the Japanese and Korean population. The discrepancy in race may be attributed to the number of studies and the number of subjects. 19 studies were conducted in Chinese participants, whereas only three were conducted in a Japanese population and two in a Korean population. More studies need to be conducted within Japanese and Korean populations so that they may be considered for further analyses. In the analysis of data stratified by cancer type, Val762Ala was only found to be significantly associated with an increased risk of gastric cancer.\textsuperscript{7,8} The results are consistent with previous meta-analyses in the pooled analysis of overall population. All four lung-cancer studies involved Chinese populations, and no association with this polymorphism and increased lung-cancer risk was found in the present meta-analysis. However, in the study by Qin et al.\textsuperscript{8} the PARP1 rs1136410 Val762Ala polymorphism was found to be associated with an increased risk of lung cancer in the overall population. This suggests that the polymorphism may play a different role in different races. Moreover, the discrepancy in cancer type may be attributed to high or low PARP1 expression levels in different tissues, and different functions of PARP1 in different cancer types with different mechanisms of carcinogenesis.\textsuperscript{8}

To the best of the authors’ knowledge, the current meta-analysis is the first study to investigate the association between the PARP1 rs1136410 Val762Ala polymorphism and cancer risk in Asians. The two most recent previous meta-analyses, published in 2014, explored the association among all races and included 18 studies in Asians.\textsuperscript{7,8} Six additional articles have been included in the present study, thus reaching a total of 24 articles in the meta-analysis. In accordance with previously published findings,\textsuperscript{7,8} the present study also found that the PARP1 rs1136410 Val762Ala polymorphism was significantly associated with an increased cancer risk in Asians. Importantly, this is the first meta-analysis to show that this polymorphism is significantly related to an increased risk of cancer in the Chinese, but not in the Japanese and Korean population. In addition, the present study is the first to find a significant association between the polymorphism and an increased risk of gastric cancer in Asians.

Several potential limitations of the current meta-analysis should also be addressed. First, in the stratification analysis, the number of studies and sample sizes were relatively small, for example, among the Japanese and Korean population. Secondly, as the original information was lacking, the present findings were based on unadjusted ORs. A more precise analysis should be conducted to explore whether individual information, such as age, sex, smoking and drinking status, and other environmental factors, are available to adjust for confounding factors. Thirdly, heterogeneity was observed among some genetic models, and the random-effects model was adopted to estimate the association. Finally, due to the lack of original data, assessment of the possible gene-gene and gene-environment interaction effects on cancer risk was limited.

In conclusion, the current meta-analysis is the first to focus on Asian populations
and provide more precise evidence that the PARP1 rs1136410 Val762Ala polymorphism is significantly associated with an increased cancer risk in the East Asian population. The same results were observed for gastric cancer in the cancer-type stratification analysis, particularly in the Chinese population. Large-scale and well-designed studies are warranted to validate the findings of this meta-analysis.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research received a specific grant from subject construction of Xijing hospital: XJZT18X12.

ORCID iD
Yijuan Xin https://orcid.org/0000-0002-0238-6651

References
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
2. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78–85.
3. Lindahl T and Wood RD. Quality control by DNA repair. Science 1999; 286: 1897–1905.
4. Wood RD, Mitchell M, Sgouros J, et al. Human DNA repair genes. Science 2001; 291: 1284–1289.
5. Schreiber V, Dantzer F, Ame JC, et al. Poly (ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7: 517–528.
6. Tong WM, Yang YG, Cao WH, et al. Poly (ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. Oncogene 2007; 26: 3857–3867.
7. Hua RX, Li HP, Liang YB, et al. Association between the PARP1 Val762Ala polymorphism and cancer risk: evidence from 43 studies. PLoS One 2014; 9: e87057.
8. Qin Q, Lu J, Zhu H, et al. PARP-1 Val762Ala polymorphism and risk of cancer: a meta-analysis based on 39 case-control studies. PLoS One 2014; 9: e98022.
9. Zhu J, Jia W, Wu C, et al. Base excision repair gene polymorphisms and Wilms tumor susceptibility. EBioMedicine 2018; 33: 88–93.
10. Zhuo Z, Zhou C, Fang Y, et al. Correlation between the genetic variants of base excision repair (BER) pathway genes and neuroblastoma susceptibility in eastern Chinese children. Cancer Commun (Lond) 2020; 40: 641–646.
11. Wang XG, Wang ZQ, Tong WM, et al. PARP1 Val762Ala polymorphism reduces enzymatic activity. Biochem Biophys Res Commun 2007; 354: 122–126.
12. He J, Liao XY, Zhu JH, et al. Association of MTHFR C677T and A1298C polymorphisms with non-Hodgkin lymphoma susceptibility: evidence from a meta-analysis. Sci Rep 2014; 4: 6159.
13. Mantel N and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–748.
14. DerSimonian R and Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
15. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
16. Shi Y, Xu W and Zhang X. Association of the hOGG1 Ser326Cys polymorphism with gynecologic cancer susceptibility: a meta-analysis. Biosci Rep 2020; 40: BSR20203245.
17. Miao X, Zhang X, Zhang L, et al. Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer. Gastroenterology 2006; 131: 420–427.
18. Nakao M, Hosono S, Ito H, et al. Selected polymorphisms of base excision repair genes and pancreatic cancer risk in Japanese. *J Epidemiol* 2012; 22: 477–483.

19. Pan XF, Xie Y, Loh M, et al. Polymorphisms of XRCC1 and ADPRT genes and risk of noncardia gastric cancer in a Chinese population: a case-control study. *Asian Pac J Cancer Prev* 2012; 13: 5637–5642.

20. Wen YY, Pan XF, Loh M, et al. ADPRT Val762Ala and XRCC1 Arg194Trp polymorphisms and risk of gastric cancer in Sichuan of China. *Asian Pac J Cancer Prev* 2012; 13: 2139–2144.

21. Zeng L, You G, Tanaka H, et al. Combined effects of polymorphisms of DNA-repair protein genes and metabolic enzyme genes on the risk of cholangiocarcinoma. *Jpn J Clin Oncol* 2013; 43: 1190–1194.

22. Zhang Z, Miao XP, Tan W, et al. Correlation of genetic polymorphisms in DNA repair genes ADPRT and XRCC1 to risk of gastric cancer. *Ai Zheng* 2006; 25: 7–10 [In Chinese, English abstract].

23. Hao B, Wang H, Zhou K, et al. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. *Cancer Res* 2004; 64: 4378–4384.

24. Zhang X, Miao X, Liang G, et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. *Cancer Res* 2005; 65: 722–726.

25. Zhai X, Liu J, Hu Z, et al. Polymorphisms of ADPRT Val762Ala and XRCC1 Arg399Glu and risk of breast cancer in Chinese women: a case control analysis. *Oncol Rep* 2006; 15: 247–252.

26. Stern MC, Conti DV, Siegmund KD, et al. DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 2363–2372.

27. Chiang FY, Wu CW, Hsiao PJ, et al. Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma. *Clin Cancer Res* 2008; 14: 5919–5924.

28. Jin XM, Kim HN, Lee IK, et al. PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males. *BMC Med Genet* 2010; 11: 38.

29. Wang M, Qin C, Zhu J, et al. Genetic variants of XRCC1, APE1, and ADPRT genes and risk of bladder cancer. *DNA Cell Biol* 2010; 29: 303–311.

30. Kim J, Pyun JA, Cho SW, et al. Lymph node metastasis of gastric cancer is associated with the interaction between poly (ADP-ribose) polymerase 1 and matrix metallopeptidase 2. *DNA Cell Biol* 2011; 30: 1011–1017.

31. Yuan H, Li H, Ma H, et al. Genetic polymorphisms in key DNA repair genes and risk of head and neck cancer in a Chinese population. *Exp Ther Med* 2012; 3: 719–724.

32. Zhang L, Ruan Z, Hong Q, et al. Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: A case-control study. *Oncol Lett* 2012; 3: 351–362.

33. Hosono S, Matsuo K, Ito H, et al. Polymorphisms in base excision repair genes are associated with endometrial cancer risk among postmenopausal Japanese women. *Int J Gynecol Cancer* 2013; 23: 1561–1568.

34. Li Y, Li S, Wu Z, et al. Polymorphisms in genes of APE1, PARP1, and XRCC1: risk and prognosis of colorectal cancer in a northeast Chinese population. *Med Oncol* 2013; 30: 505.

35. Tang LY, Chen LJ, Qi ML, et al. Effects of passive smoking on breast cancer risk in pre/post-menopausal women as modified by polymorphisms of PARP1 and ESR1. *Gene* 2013; 524: 84–89.

36. Xue X, Yin Z, Lu Y, et al. The joint effect of hOGG1, APE1, and ADPRT polymorphisms and cooking oil fumes on the risk of lung adenocarcinoma in Chinese non-smoking females. *PLoS One* 2013; 8: e71157.

37. Wang X, Ma KW, Zhao YG, et al. XRCC1 rs25487 polymorphism is associated with lung cancer risk in epidemiologically susceptible Chinese people. *Genet Mol Res* 2015; 14: 15530–15538.
38. Yu P, Liu YP, Zhang JD, et al. Correlation between PARP-1 Val762Ala polymorphism and the risk of lung cancer in a Chinese population. *Tumour Biol* 2015; 36: 177–181.

39. Cheng J, Zhuo Z, Zhao P, et al. PARP1 gene polymorphisms and neuroblastoma susceptibility in Chinese children. *J Cancer* 2019; 10: 4159–4164.

40. Deng Y, Zhou L, Li N, et al. Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: A case-control study. *Mol Carcinog* 2019; 58: 2218–2229.

41. Heinen CD, Schmutte C and Fishel R. DNA repair and tumorigenesis: lessons from hereditary cancer syndromes. *Cancer Biol Ther* 2002; 1: 477–485.

42. Yu H, Ma H, Yin M, et al. Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis. *Genet Epidemiol* 2012; 36: 56–65.

43. Masutani M, Nakagama H and Sugimura T. Poly(ADP-ribose) and carcinogenesis. *Genes Chromosomes Cancer* 2003; 38: 339–348.